BioSpace News Archive

HR Pharmaceuticals, Inc. announced the introduction of CliniClean Chlorhexidine Gluconate 4%, an antiseptic solution providing maximum coverage to protect the skin against various microorganisms while reducing the risk of acquiring a healthcare-associated infection or surgical site infection.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open.

Celularity Inc. announced that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the Stratys™ system for high throughput optical genome mapping (OGM) and VIA™ software for visualization, interpretation and reporting of genome analysis for OGM, microarrays and next-generation sequencing (NGS) data in one integrated software platform.

Merus N.V. (Nasdaq: MRUS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) pancreatic cancer following progression with prior systemic therapy or who have no satisfactory alternative treatment options.

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023").

Renalytix plc announces that the U.S. Food and Drug Administration has granted De Novo marketing authorization for its KidneyIntelX.dkd ™ prognostic test.

Intensity Therapeutics, Inc. announced the pricing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.

MedMira Inc., reported on its financial results for the quarter ended April 30, 2023.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.